Table 1.
Details of the studies and participants included*
| Study | No. |
Mean (SD) age at sample collection, y |
Median (IQR) selenium concentration (nmol/L for blood; ppm for nails) |
|||
|---|---|---|---|---|---|---|
| Case patients | Control subjects | Case patients | Control subjects | Case patients | Control subjects | |
| Blood selenium | ||||||
| BLSA (8) | 55 | 55 | 69.1 (8.6) | 68.8 (7.7) | 1431 (1317–1671) | 1532 (1418–1684) |
| CARET (13) | 235 | 456 | 61.5 (6.1) | 61.3 (6.2) | 1462 (1280–1599) | 1425 (1282–1595) |
| EPIC (17) | 959 | 1,059 | 59.9 (5.8) | 59.6 (5.8) | 898 (791–1022) | 910 (809–1027) |
| EPIC-Heidel (19) | 148 | 291 | 57.4 (5.1) | 57.8 (5.1) | 1100 (1010–1230) | 1100 (994–1210) |
| FMC (15) | 51 | 92 | 65.5 (7.7) | 65.4 (7.4) | 709 (582–912) | 734 (595–893) |
| MEC (18) | 461 | 920 | 69.0 (7.0) | 68.8 (7.1) | 1708 (1582–1865) | 1718 (1594–1871) |
| NPC (2) | 41 | 123 | 66.9 (5.0) | 66.8 (4.9) | 1433 (1256–1570) | 1433 (1241–1605) |
| PCPT (unpublished) | 960 | 960 | 63.4 (5.5) | 63.3 (5.6) | 1687 (1544–1845) | 1660 (1529–1830) |
| PHS (10) | 794 | 794 | 59.0 (8.2) | 58.8 (8.1) | 1374 (1221–1532) | 1371 (1223–1545) |
| PLCO (16) | 723 | 879 | 65.1 (4.8) | 64.8 (4.7) | 1775 (1589–1946) | 1797 (1605–2000) |
| SU.VI.MAX (unpublished) | 100 | 392 | 55.1 (4.6) | 55.0 (4.6) | 1115 (1026–1252) | 1127 (995–1254) |
| Nail selenium | ||||||
| CLUE II (14) | 117 | 233 | 65.9 (7.5) | 65.9 (7.5) | 0.77 (0.68–0.86) | 0.79 (0.70–0.87) |
| HPFS (11) | 181 | 181 | 63.2 (6.4) | 63.1 (6.4) | 0.79 (0.70–0.91) | 0.80 (0.73–0.94) |
| NLCS (12, 49) | 1268 | 1268 | 62.7 (4.1) | 62.7 (4.1) | 0.51 (0.46–0.57) | 0.54 (0.48–0.60) |
| SELECT (4) | 404 | 404 | 63.3 (6.0) | 62.7 (4.1) | 0.87 (0.79–0.97) | 0.88 (0.77–0.99) |
The numbers of case patients and control subjects are the number for whom selenium measurements were available. BLSA = Baltimore Longitudinal Study of Aging; CARET = the beta-Carotene and Retinol Efficacy Trial; CLUE II = Campaign against Cancer and Stroke (“Give us a Clue to Cancer”) Study; EPIC = European Prospective Investigation into Cancer and Nutrition; EPIC-Heidel = EPIC-Heidelberg; FMC = Finnish Mobile Clinic Health Examination Survey; HPFS = Health Professionals Follow-up Study; MEC = Multiethnic Cohort; NLCS = Netherlands Cohort Study; NPC = Nutritional Prevention of Cancer Trial; PCPT = Prostate Cancer Prevention Trial; PHS = Physicians’ Health Study; PLCO = Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; SELECT = Selenium and Vitamin E Cancer Prevention Trial; SU.VI.MAX = SUpplémentation en VItamines et Minéraux Anti-oXydants Trial.